2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
Benefits and risks of moderate alcohol consumption on cardiovascular disease: current findings and controversies
G Chiva-Blanch, L Badimon - Nutrients, 2019 - mdpi.com
Alcohol has a hormetic physiological behavior that results in either increased or decreased
cardiovascular risk depending on the amount consumed, drinking frequency, pattern of …
cardiovascular risk depending on the amount consumed, drinking frequency, pattern of …
US life expectancy stalls due to cardiovascular disease, not drug deaths
NK Mehta, LR Abrams… - Proceedings of the …, 2020 - National Acad Sciences
After decades of robust growth, the rise in US life expectancy stalled after 2010.
Explanations for the stall have focused on rising drug-related deaths. Here we show that a …
Explanations for the stall have focused on rising drug-related deaths. Here we show that a …
2022 ACC/AHA/HFSA guideline for the management of heart failure
ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
Has the first year of the COVID-19 pandemic reversed the trends in CV mortality between 1999 and 2019 in the United States?
O Kobo, D Abramov, M Fudim, G Sharma… - … Journal-Quality of …, 2023 - academic.oup.com
Aims Although cardiovascular (CV) mortality increased during the COVID-19 pandemic, little
is known about how these patterns varied across key subgroups, including age, sex, and …
is known about how these patterns varied across key subgroups, including age, sex, and …
Stimulant drugs of abuse and cardiac arrhythmias
P Dominic, J Ahmad, H Awwab… - Circulation …, 2022 - Am Heart Assoc
Nonmedical use of prescription and nonprescription drugs is a worldwide epidemic, rapidly
growing in magnitude with deaths because of overdose and chronic use. A vast majority of …
growing in magnitude with deaths because of overdose and chronic use. A vast majority of …
DASH-HF study: a pragmatic quality improvement randomized implementation trial for patients with heart failure with reduced ejection fraction
A Verma, GC Fonarow, JJ Hsu… - Circulation: Heart …, 2023 - Am Heart Assoc
BACKGROUND: Heart failure is a prevailing diagnosis of hospitalization and readmission
within 6 months, and nearly a quarter of these patients die within a year. Guideline-directed …
within 6 months, and nearly a quarter of these patients die within a year. Guideline-directed …
Methamphetamine‐associated heart failure hospitalizations across the United States: geographic and social disparities
Background Although methamphetamine abuse is associated with the development of heart
failure (HF), nationwide data on methamphetamine‐associated HF (MethHF) …
failure (HF), nationwide data on methamphetamine‐associated HF (MethHF) …
Methamphetamine-associated heart failure: a systematic review of observational studies
Objective To conduct a systematic review of observational studies on methamphetamine-
associated heart failure (MethHF). Methods Six databases were searched for original …
associated heart failure (MethHF). Methods Six databases were searched for original …
Cardiomyopathy-associated hospital admissions among methamphetamine users: geographical and social disparities
Background Methamphetamine is an emerging drug threat. The disparity in cardiomyopathy-
associated hospital admissions among methamphetamine users (CAHMA) over the decade …
associated hospital admissions among methamphetamine users (CAHMA) over the decade …